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cDNAs encoding the bovine immunodeficiency virus (BIV) transactivator gene (tat) were cloned from virally infected cells
and characterized. BIV expresses two distinct tat mRNAs composed of three exons that are derived by alternative splicing.
The BIV tat mRNA splice variants encode Tat proteins of 103 (Tat103) and 108 (Tat108) amino acids. The Tat103 coding
region is specified only by exon 2, while that of Tat108 is specified by a truncated exon 2 and the first 30 nt of exon 3.
Thus, the first 98 amino acids of each Tat are identical, and have amino terminal, cysteine-rich, conserved core, basic, and
carboxyl-terminal domains similar to Tats encoded by primate lentiviruses. BIV-infected bovine cells express a 14-kDa
phosphorylated Tat protein identical in size to recombinant Tat expressed in bacteria. BIV Tat was shown to localize
exclusively in the nucleoli of virally infected and Tat-expressing cells. Reporter gene assays indicated that Tat103 and
Tat108 can strongly transactivate the BIV long terminal repeat (LTR) in virally permissive canine Cf2Th and nonpermissive
HeLa and mouse NIH 3T3 cells, but not in permissive lapine EREp cells. However, an intact BIV tat gene is required for
viral replication in both Cf2Th and EREp cells. Strong LTR activation by BIV Tat requires a TAR (transactivation responsive)
element delimited by viral nt /1 to /31 and the Tat basic domain. BIV Tat strongly cross-transactivates the HIV-1 LTR in
a TAR-dependent manner in Cf2Th, but not in EREp, HeLa, or NIH 3T3 cells. In contrast, strong, TAR-dependent cross-
transactivation of the BIV LTR by HIV-1 Tat could not be demonstrated in any of these cell types. In Cf2Th cells Tat108
effects a moderately stronger transactivation of the BIV LTR than Tat103, indicative of a functional difference in BIV Tat
proteins encoded by the mRNA splice variants. The present studies demonstrate that BIV Tat parallels the primate lentiviral
Tats in structure and biochemistry but is not interchangeable with the latter. q 1997 Academic Press
INTRODUCTION et al., 1990; reviewed in Gonda et al., 1994). In addition
to genes encoding the obligate retroviral Gag, Pol, and
Bovine immunodeficiency virus (BIV) is a nonacute,
Env structural proteins, BIV contains genes (tat, rev, vif,
horizontally transmitted, pathogenic lentivirus of cattle,
vpy, vpw, and tmx) for six putative nonstructural/acces-
and a member of one of seven evolutionarily distinct
sory proteins that reside between and/or overlap the pollentivirus groups (reviewed in Gonda et al., 1994). The
and env genes (Garvey et al., 1990; Liu et al., 1992; Ober-genome structure of BIV is the most complex of the non-
ste et al., 1993; Gonda, 1994; Gonda et al., 1994). One ofprimate lentiviruses and bears strong similarity to the
these, tat, encodes a protein that transactivates geneprimate lentiviruses, simian immunodeficiency virus
expression directed by the viral long terminal repeat(SIV), and human immunodeficiency virus types 1 and 2
(LTR) (Liu et al., 1992; Pallansch et al., 1992; Carpenter(HIV-1 and HIV-2), the causative agents of AIDS in mon-
et al., 1993; Fong et al., 1995).keys and man, respectively (Braun et al., 1988; Garvey
Tat proteins are encoded by all lentiviruses thus far
studied and can be categorized into two functional
1 The U.S. Government’s right to retain a nonexclusive royalty-free groups. The first group includes Tats encoded by BIV
license in and to the copyright covering this paper, for governmental (Liu et al., 1992; Pallansch et al., 1992; Chen and Frankel,
purposes, is acknowledged.
1994; Puglisi et al., 1995), equine infectious anemia virus2 To whom correspondence and reprint requests should be ad-
(EIAV) (Dorn et al., 1990; Carvalho and Derse, 1991), SIVdressed at current address: Laboratory of Leukocyte Biology, NCI-Fred-
erick Cancer Research and Development Center, Frederick, MD 21702- (Arya et al., 1987; Arya, 1988), HIV-1 (Muesing et al.,
1201. Fax: (301) 846-6107. E-mail: Fong@mail.ncifcrf.gov. 1987), and HIV-2 (Arya et al., 1987; Berkhout et al., 1990).
3 Current address: Frederick Research Center, Southern Research Transactivation by these proteins is mediated by bindingInstitute, Frederick, MD 21701.
to RNA encoded by a transactivation responsive (TAR)4 Current address: Genovo, Inc., P.O. Box 42884, Philadelphia, PA
19101. element located immediately downstream of the viral cap
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site. The function of HIV-1 Tat has been extensively stud- exception to this pattern occurred in Cf2Th cells, which
permitted strong, TAR-dependent cross-transactivationied and described as essential for transactivation of virus
gene expression and efficient virus replication (Dayton of the HIV-1 LTR by BIV Tat.
et al., 1986; Fisher et al., 1986; Dimitrov et al., 1993). The
second group includes Tats encoded by feline immuno- MATERIALS AND METHODS
deficiency virus (FIV) (Sparger et al., 1992), caprine arthri-
Virus and cell culturetis encephalitis virus (CAEV) (Hess et al., 1986), and visna
virus (Hess et al., 1985; Davis and Clements, 1989). Cf2Th, BLAC-20, and EREp cells permissive for BIV
These lentiviruses lack TAR sequences and thus trans- infection have been described previously (Pallansch et
activate virus replication in a TAR-independent manner. al., 1992; Pifat et al., 1992; Fong et al., 1995). These and
Previous studies of cDNAs derived from BIV-infected Hela cells were grown in Dulbecco’s modified Eagle me-
cells have suggested that BIV Tat is encoded by a single, dium supplemented with 10% fetal bovine serum and 100
multiply spliced mRNA species consisting of three exons U/ml penicillin/streptomycin in a humidified atmosphere
in which only the second exon codes for a tat product containing 5% CO2 . NIH 3T3 cells were cultured similarly
(Liu et al., 1992). Alignment of the BIV Tat amino acid except that bovine calf serum was substituted for fetal
sequence with those of the primate lentiviruses indicates bovine serum. To prepare BIV-infected cells for isolating
the presence of five common structural domains: acidic Tat cDNAs and studying Tat expression, Cf2Th, BLAC-
amino-terminal, cysteine-rich, conserved core, basic, and 20, and EREp cells were infected with progeny of either
carboxyl-terminal (Dorn et al., 1990; Liu et al., 1992; BIV106 and BIV127 infectious molecular clones (Braun
Gonda et al., 1994). Interestingly, BIV Tat exhibits features et al., 1988) and cultured as previously described (Ober-
of both Tat groups in that it strongly activates LTR-di- ste et al., 1993).
rected gene expression in a TAR-dependent manner in
virally permissive canine (Cf2Th) cells, but only weakly Cloning and sequencing of tat cDNAs
activates gene expression in a TAR-independent manner
Total RNA was extracted from BIV106-infected BLAC-in virally permissive bovine (BLAC-20) and lapine (EREp)
20 cells, and tat cDNAs were prepared by reverse tran-cells (Fong et al., 1995).
scription and polmerase chain reaction (PCR) amplifica-Biochemical and genetic studies indicate that the ba-
tion as previously described for rev cDNAs (Oberste etsic domain of BIV Tat mediates binding to BIV TAR RNA
al., 1993). The primers used for cDNA synthesis wereand that transactivation does not require the cooperative
based on the BIV106 genomic sequence (Garvey et al.,effect of cellular cofactors (Chen and Frankel, 1994; Pug-
1990), with the primer for reverse transcription being 5*-lisi et al., 1995). However, a requirement for the basic
CGGCCTAACCACAATCAGC-3*, encompassing nucleo-domain of BIV Tat in transactivation has not been verified,
tides 8209 through 8191 of the 3* LTR, and the primersand it has not been demonstrated whether the similar
for PCR amplification being 5*-TAAGAGAGACTCGGCTC-domain structures of BIV and the primate Tats reflect
GAG-3*, encompassing nt 229 through 248 of the com-equivalent functional properties in vitro. BIV Tat has also
mon splice donor at the 5* end of the genome, and 5*-been shown to cross-transactivate the HIV-1 LTR. How-
CGGCCTAACCACAATCAGC-3*, encompassing nt 8208ever, the mechanism and functional necessity of TAR
to 8191 of the 3* LTR. The PCR products were clonedsequences in this activity has not been elucidated (Liu
into the SmaI site of M13mp18 and sequenced. tatet al., 1992).
cDNAs were identified by their homology to the pub-In this study, a comprehensive analysis of the BIV tat
lished sequence of BIV106 (Garvey et al., 1990) and aregene and its product was performed. DNA sequencing
shown in Fig. 1 and Table 1.of BIV tat cDNA clones demonstrated that BIV Tat is
encoded by two distinct mRNA splice variants specifying Construction of prokaryotic and eukaryotic BIV Tat
proteins that are identical except for their carboxyl-termi- expression plasmids
nal sequences. These two proteins were found to differ
in the strength with which they transactivate the BIV LTR tat cDNA clones were not available at the beginning
of this study. To create a prokaryotic BIV Tat expressionin one cell type (Cf2Th cells) but not in several other cell
lines tested. We show that BIV Tat is a 14-kDa phosphory- plasmid, putative tat coding sequences were PCR ampli-
fied from BIV127 and cloned into the T7 promoter vectorlated protein that is preferentially localized in the nucleo-
lus and parallels the primate lentivirus Tats in require- pT5m (Studier and Moffatt, 1986) as follows. Nucleotides
5228 to 5539 were amplified with the forward primer 5*-ment for replication, biochemistry, and function. BIV and
HIV-1 Tat were not found to be functionally interchange- TGGCAccATGgCCGGACCT-3* (nt 5221 to 5239) and the
reverse primer 5*-CCTAGTAGCATTCCTACTCC-3* (ntable, as they were unable to strongly cross-transactivate
each other’s LTRs in a TAR-dependent manner in several 5602 to 5583). The forward primer mutated the BIV se-
quence at nt 5626, 5627, and 5631 (bases in lower case)cell lines tested (Hela, EREp, and NIH 3T3). However, an
AID VY 8589 / 6a39$$$201 06-06-97 13:15:49 viras AP: Virology
341BIV tat GENE AND PRODUCTS
to engineer an NcoI site (bold) at the Met initiator for tat; Construction of a BIV provirus deficient in Tat
functionthe reverse primer was downstream of an NcoI site in
the BIV127 sequence. The PCR product was restricted
To create a Tat-deficient provirus the infectious BIV127with NcoI, ligated into pT5m to create vector pT5m-Tat,
proviral molecular clone pACYC184-BIV127 (Garvey etand transformed into competent Escherichia coli strain
al., 1990) was cleaved at a unique PmlI site (nt 5305) inBL21DESpLysS(CmR) to permit induction of the T7 pro-
the tat open reading frame, and a linker with the se-moter in pT5m with isopropylthio-b-D-galactoside (IPTG).
quence 5*-GTAGCGCGCTAC-3* was inserted. This inser-When tat cDNA clones were identified in these studies,
tion disrupted Tat translation by the introduction of a TAGmammalian cell tat expression vectors were constructed
stop codon (bold) 30 amino acids from the Met initiator.using a PCR amplification strategy. The cDNA inserts in
It also adds four amino acids to the carboxyl-terminalM13mp8 clones 110 and 108, representing the tat RNA
region of the putative regulatory nonstructural gene prod-splice variants tat 103 and tat 108, respectively (Table
uct of vpy (Garvey et al., 1990). The BIV provirus clone1), were amplified with the forward primer 5*-CATGAT-
with an interrupted tat gene and the parental proviralTGTGCGGCCGCATGCCCGGA-3* (nt 5212–5236) con-
clone were designated pBIV127Dtat and pBIV127, respec-taining a NotI site (underlined) immediately upstream of
tively.the tat initiator (bold), and the reverse primer 5*-ATACCA-
AGCCGGGCCCGTTATTGATCCAT-3* (nt 8105–8080)
Measurement of Tat function on virus replication
containing an ApaI site (underlined). Both PCR products
were restricted with NotI and ApaI and cloned into NotI To assay the replication of viruses encoded by pBIV-
and ApaI sites located downstream of the cytomegalovi- 127Dtat and pBIV127, Cf2Th, Cf2Th-Tat103, and EREp
rus early promoter in the mammalian cell expression cells were plated on 12-well dishes at a density of 2 1
plasmid pRcCMV (Invitrogen, San Diego, CA). The tat 103 104 cells per well and transfected with 10 mg of proviral
and tat 108 pRcCMV mammalian expression plasmids DNA and 15 mg of DOTAP transfection reagent using
were designated pTat103 and pTat108, respectively. The previously described methods (Fong et al., 1995). The
proteins encoded by these plasmids are 103 and 108 day after transfection the cells were passaged to 75-
amino acids long and were designated Tat103 and cm2 flasks. At 3-day intervals after this transfer, 1.0-ml
Tat108, respectively (Table 1). aliquots of medium were removed from the flasks, centri-
fuged briefly to remove cells, mixed with 0.5 ml of 30%
Construction of Tat cell lines (vol/vol) polyethylene glycol, and incubated overnight at
47. Precipitated virus particles in these samples wereTo produce cell lines stably expressing BIV Tat, Cf2Th
pelleted, solubilized in 200 ml of lysis buffer containingcells were transfected with plasmids pTat103 or pTat108,
50 mM Tris–Cl (pH 7.8), 5 mM EDTA, 100 mM NaCl,using the cationic liposome DOTAP, N-[1-(2,3-dioleoyl-
0.5% CHAPS (3-[(3-chloamidopropyl)-dimethylammonio]-oxy)propyl]-N,N,N-trimethylammonium methyl sulfate
1-propane sulfonate (Sigma), and 0.5% deoxycholate, and(Boehringer-Mannheim, Indianapolis, IN) as instructed by
assayed for the presence of the viral p26 protein by athe manufacturer. Following transfection, the medium
BIV p26 antigen-capture ELISA as described (Tobin etwas supplemented with 500 mg of G418 (Sigma, St. Louis,
al., 1996; Battles et al., manuscript in preparation).MO) per milliliter. Cells surviving G418 drug selection
were screened for Tat expression by Western blot analy- Peptide synthesis and generation of Tat-specific
sis with rabbit antibodies raised to the Tat peptide. Cf2Th antisera
lines stably expressing Tat103 and Tat108 were desig-
nated Cf2Th-Tat103 and Cf2Th-Tat108, respectively. To create BIV Tat-specific antisera, two peptides, GVN-
YGSGPRPRGTRGLL (Tat-2) and READSQRSFTNMDQ
Construction of vectors expressing truncated Tat (Tat-3), corresponding to residues 60 to 76 and 90 to 103
proteins of the Tat103 sequence, respectively, were synthesized
by solid-phase methods (Merrifield, 1963) and conju-
To construct mammalian cell expression vectors in
gated to hemocyanin (Oberste et al., 1993). Sera con-
which portions of the BIV Tat open reading frame were
taining Tat antibodies were prepared from New Zealand
deleted, a previously described plasmid, pRBIVTat, was
White rabbits immunized with hemocyanin-conjugated
utilized that contained the BIV tat 103 sequence under
Tat-2 or Tat-3 peptide or rats immunized with bacterially
the control of the Rous sarcoma virus promoter (Fong et
expressed Tat.
al., 1995). Using an overlap extension PCR protocol (Ho
et al., 1989), TCA codons (specifying serine) at residues Radioimmunoprecipitation assays (RIPA)
65 and 84 of the BIV tat 103 sequence were changed to
TGA stop codons to create plasmids pTat64 and pTat83, BIV Tat expressed in mammalian cells or E. coli was
detected by RIPA as previously described (Rasmussenrespectively.
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et al., 1990; Battles et al., 1992; Oberste et al., 1993). contained the first 71 bp of the BIV 5*-LTR (Garvey et al.,
1990), plus bases at its 5*- and 3*-ends compatible withBriefly, uninfected or BIV-infected Cf2Th, EREp, or BLAC-
20 cells were labeled for 1 hr with [35S]methionine and those generated by HindIII and XhoI, respectively. These
complementary oligonucleotides encompassed a unique[35S]cysteine or [32Pi] (Amersham), lysed, and immunopre-
cipitated. For recombinant protein expressed in E. coli, BamHI site present at nt 65 of the BIV LTR. The oligonu-
cleotide insertion plasmid was digested with BamHI andbacteria were labeled with [35S]methionine and [35S]-
cysteine, lysed, and immunoprecipitated as described XhoI, and the released fragment was discarded and re-
placed with a 460-bp BamHI–XhoI restriction endonucle-(Hizi et al., 1988). Immunoprecipitated proteins were sep-
arated on sodium dodecyl sulfate–16% polyacrylamide ase fragment from the BIV LTR chloramphenicol acetyl-
transferase vector pBLTRCAT (Fong et al., 1995). Thegels and visualized by autoradiography.
final vector, pBLTRLuc, contained the complete 496-bp
Indirect immunofluorescence assays and BIV LTR U3 and R sequence, plus the first 33 bp of the
immunoelectron microscopy U5 region, in front of the luciferase reporter gene.
To construct derivatives of pBLTRLuc in which portions
Tat was localized in BIV-infected Cf2Th cells by indi-
of the R region were deleted, an overlap extension PCR
rect immunofluorescence. Infected cells were grown to
protocol was utilized (Ho et al., 1989). Deletions were
approximately 50% confluence on 10-mm2 glass cov-
made between unique AccI and XhoI sites in pBLTRLuc
erslips, washed briefly in PBS, fixed, and permeabilized
that corresponded to BIV127 genome nt positions 178
for 6 min in a 1:1 mixture of methanol:acetone at room
and 525. The final constructs were designated pTD1-32,
temperature, allowed to air dry, and incubated for 15 min
pTD32-69, pTD44-102, and pTD1-111 and contained R
in a blocking solution consisting of 0.1% bovine serum
region deletions of nt 1 to 32, 32 to 69, 44 to 102, and 1
albumin (BSA) and 10% normal goat serum in PBS. The
to 111, respectively.
fixed and blocked cells were incubated for 30 min at 377
To construct HIV-1 LTR luciferase reporter gene vec-
with rabbit anti-Tat-3 peptide serum diluted 1:25 in 0.1%
tors, a 1.7-kilobase-pair (kb) HindIII/XbaI restriction endo-
BSA/PBS. Following incubation, the coverslips were
nuclease fragment from pXP2, encompassing the entire
washed for 30 min in 0.1% BSA/PBS, incubated for 30 min
luciferase open reading frame plus polyadenylation sig-
at 377 in a solution containing 2.5 mg/ml of fluorescein-
nals, was subcloned into pUC18. The luciferase gene
conjugated, affinity purified goat anti-rabbit IgG (Kirke-
was excised by restricting at the HindIII site plus a BamHI
gaard and Perry), washed with 0.1% BSA/PBS again, and
site present in the pUC18 multisite cloning cassette, and
counterstained with Evans blue reagent (ViroStat, Port-
the released fragment was used to replace the HindIII/
land, ME) diluted 1:100 in water. The stained cover slips
BamHI CAT gene sequences in the HIV-1 LTR reporter
were mounted on glass slides using 10% glycerol and
gene vector pC15CAT (Arya et al., 1985), and pHDTAR-
visualized and photographed using a fluorescence-
CAT, a derivative of pC15CAT in which the HIV-1 TAR
equipped Zeiss Axioskop epifluorescence microscope
stem-loop between nt /24 and /35 was deleted. The
with a 35-mm camera attachment.
pC15CAT and pHTARCAT luciferase gene derivatives
Immunoelectron microscopy of Tat-expressing cells
were designated pHLTRLuc and pHdTARLuc, respec-
was performed using previously described preembed-
tively.
ding procedures (Rasmussen et al., 1990; Tobin et al.,
1996). Briefly, cells were stained with rabbit anti-Tat-3
Transient reporter gene expression assayspeptide serum, followed by colloidal gold-labeled goat
anti-rabbit IgG. Immunolabeled sections were stained for
To conduct transient luciferase reporter gene assays,
transmission electron microscopy and visualized using
Cf2Th, EREp, NIH3T3, and Hela cells were grown to ap-
a Hitachi H-7000 electron microscope.
proximately 50% confluence in 75-cm2 flasks, plated at 2
1 104 cells per well in 1.0 ml of culture medium onConstruction of LTR-luciferase reporter gene vectors
12-well dishes, and transfected with DNA as previously
described (Fong et al., 1995). For all cell types, 1.0 mg ofTo construct a BIV LTR-luciferase reporter gene vector,
a unique BamHI site in the multisite cloning cassette of reporter gene DNA, 0 to 0.5 mg of Tat plasmid DNA, and
10 mg of DOTAP transfection agent was used per well.the luciferase vector pXP2 (Nordeen, 1988) was de-
stroyed by restricting the site, filling in the ends with the The medium was changed 1 day after transfection. Three
days after transfection the cells were washed in PBS andKlenow fragment of DNA polymerase I, and religating.
The resulting plasmid was cleaved at unique HindIII and lysed in 200 ml of a buffer containing 1% Triton X-100, 25
mM Tris, pH 7.8, 2 mM EDTA, 2 mM dithiothreitol, andXhoI restriction endonuclease sites present in the
multisite cassette downstream of the ablated BamHI site. 10% glycerol. One hundred microliters of this extract was
mixed with 100 ml of luciferase assay reagent (Promega,The released fragment was discarded and replaced with
complementary oligonucleotides that, after annealment, Madison, WI) and light output over a 1-sec interval moni-
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tored with a Wallac model 1450-014, Microbeta Plus liq- BIV tat 103 encodes a 14-kDa protein
uid scintillation counter.
The predicted molecular weights of Tat103 and Tat108
are 11.7 and 12.2 kDa, respectively. To verify whether tat
RESULTS 103 encodes a protein of the predicted size, the expres-
sion vector pT5m-Tat103 was used to transform E. coli,BIV encodes two distinct tat cDNAs
and extracts from uninduced and IPTG-induced bacteria
Four cDNAs containing the entire tat coding region were probed by RIPA using a Tat-specific peptide anti-
were made by reverse transcription and PCR amplifica- body, Tat-2. This antibody recognized a 14-kDa protein
tion of total cellular RNA from BIV106-infected BLAC- in induced but not uninduced bacteria (Fig. 3A, lanes 1
20 cells. DNA sequencing revealed that these cDNAs and 2, respectively). The slower migration relative to the
encode genes for two different Tat splice variants, each predicted size is probably due to the high pI (10.16) of
consisting of three exons (Figs. 1A and 1B). Three of the Tat103.
cDNAs, clones 81, 110, and 123, encode a Tat species
of 103 amino acids. The fourth, clone 108, encodes a BIV Tat is expressed in virally infected cells
species of 108 residues (Fig. 1B; Table 1). We designated
To determine whether BIV Tat is expressed in virallythe 103 and 108 amino acid cDNA species tat 103 and
infected cells, BLAC-20 cells chronically infected withtat 108 and their predicted protein products Tat103 and
BIV127 were metabolically labeled with [35S]methionineTat108, respectively. The first exon is identical in both
and [35S]cysteine and lysates from the cells probed bytat variants and includes sequences of the noncoding
RIPA with antisera to Tat-2, Tat-3, or recombinant Tat103common viral leader to a splice donor/acceptor at nt 289/
protein. All three antisera immune precipitated a 14-kDa5112. The variants differ in the position of the second
protein species from virally infected cells, but not fromsplice donor/acceptor. For the tat 103 clones that site is
uninfected cells (Fig. 3A, lanes 3 through 8). The 14-kDaat nt 5541/7638, whereas for the tat 108 clone the site
protein from the infected cells was equivalent in size tois at nt 5521/8056. In the tat 103 clones, the second exon,
recombinant Tat103 precipitated with Tat-2 antisera (Fig.delimited by nt 5112 to 5541, constitutes the only coding
3A, lane 1), suggesting that any potential posttransla-exon, and contains a tat open reading frame that begins
tional modification to BIV Tat in mammalian cells did not116 nt past the first splice junction and ends at a stop
alter its electrophoretic gel migration. Results similar tocodon located immediately 5* of the second splice junc-
these were also obtained with virally infected Cf2Th andtion. Exon 3, extending from nt 7638 to the end of full-
EREp cells (data not presented).length viral transcripts, is noncoding because of this
stop. The predicted amino acid sequences for the three
BIV encodes a 14-kDa phosphorylated protein thattat 103 cDNAs differ from each other and the BIV Tat103
potentially oligomerizes in mammalian cellsclone described by Liu et al. (1992) in the three residues
indicated in Table 1. For tat 108, the alternative splicing To determine if BIV Tat is phosphorylated, BIV-infected
at nt 5521/8056 causes the loss of 5 amino acids in the Cf2Th cells were metabolically labeled with 32Pi , and ly-
translation of exon 2 and adds 10 amino acids originating sates from these cells analyzed by RIPA with Tat-3 anti-
from exon 3. Starting at amino acid 99, Tat108 has the sera. As a positive control, RIPA was also performed with
sequence PGNKTTQKGD (exon 3 sequences under- a rabbit antiserum to BIV Rev protein, which has been
lined), versus TNMDQ for Tat103. shown to be phosphorylated in Cf2Th cells (Oberste et
al., 1993). The Tat antisera precipitated labeled proteins
Sequence and structural similarities of BIV and which migrated at 14 and 28 kDa (Fig. 3B, lane 2). The
primate lentivirus Tat proteins Rev antisera precipitated a more intensely labeled pro-
tein of 23 kDa (Fig. 3B, lane 3). No precipitates were
Based on a PILEUP multiple sequence global align-
detected using negative control sera from rabbits that
ment program (Feng and Doolittle, 1987), Tat103 and
were not inoculated with Tat protein (Fig. 3B, lane 1).
Tat108 are more closely related to Tat proteins en-
coded by those lentiviruses which demonstrate a TAR- BIV Tat localizes in the nucleolus
dependent Tat activity (Fig. 2A). Alignment of the tat
108 sequence with that of HIV-1 (Fig. 2B) shows con- To determine the cellular localization of BIV Tat we
carried out immunoelectron microscopy using peptidesiderable similarity in structure, including the presence
of conserved cysteine-rich and core domains impli- antisera to Tat-2 and Tat-3. Because interactions be-
tween Tat and other viral or cellular proteins activatedcated in transcriptional activation and a basic domain
implicated in TAR RNA binding and nuclear localization during infection might influence localization, detection
was initially carried out using BIV-infected Cf2Th cells(Rappaport et al., 1989; Ruben et al., 1989; Cullen, 1992;
Frankel, 1992). rather than cell lines constitutively expressing Tat. The
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FIG. 1. DNA sequences of the BIV (A) tat 103 and (B) BIV tat 108 splice variant cDNAs in the form of the viral RNA. Splice junctions (sj)
are indicated by arrows. Amino acids encoded by the tat open reading frame are shown below the sequence. Nucleotides in uppercase
letters are those determined from sequencing the tat 103 (M13mp8 tat clone 110) cDNA (Table 1); lowercase letters are those deduced from
the published BIV106 DNA sequence (Garvey et al., 1990) and predicted to be in the tat viral mRNA. Underlined nucleotides represent
oligonucleotide primers used in the reverse transcription and PCR reactions. R-U5 and U3-R boundaries are indicated for reference.
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FIG. 1—Continued
Tat-2 and Tat-3 antisera did not recognize any proteins Tat108 was placed under the control of the cytomegalovi-
in uninfected Cf2Th cells (Fig. 4A) but did recognize Tat rus promoter (pTat103 and pTat108, respectively), and
in BIV-infected cells (Fig. 4B). BIV Tat almost exclusively two derivatives of the Tat103 expression plasmid pRBIV-
localized in the nucleoli, with visualization being espe- Tat (Fong et al., 1995) that expressed truncated Tat pro-
cially apparent in the giant, multinucleated syncytial cells teins (Fig. 2B). One derivative (pTat64) contained a stop
typical of BIV-infected cultures. An identical nucleolar codon after residue 64 that prevented translation of the
localization was also observed with Cf2Th cells stably basic and carboxyl-terminal regions between residues
expressing Tat103 (data not shown). 65 and 103, but permitted expression of the amino termi-
The localization of BIV Tat was also studied by post- nal, cysteine-rich, and conserved core regions between
embedding immunoelectron microscopy on thin-sec- residues 1 and 64. The second (pTat83) contained a stop
tions of BIV-infected Cf2Th cells using antiserum to codon after residue 83 that prevented translation of the
Tat-3. Consistent with the indirect immunofluorescent carboxyl-terminal region only. We also constructed a re-
staining results, the immunogold marker almost exclu- porter gene construct, pBLTRLuc, in which the BIV LTR
sively localized over dense-staining regions of nucleoli U3 and R region directed synthesis of luciferase, and
in BIV-infected cells, with little or no staining occurring derivatives of pBLTRLuc (pTD1–31, pTD32–69, pTD44–
in the electron lucent regions as was previously found 102, and pTD1–111) in which portions of the R region
for BIV Rev (Oberste et al., 1993) (Figs. 5B and 5C). No were deleted. Based on an MFOLD RNA secondary
staining occurred with uninfected cells (Fig. 5A). structure prediction program (Zuker and Stiegler, 1981)
the R region encodes a transcript having three stem-
The Tat basic domain and TAR RNA stem-loop 1 are loops (Fig. 6A). In pTD1–31, a structure defined by nt 1
required for transactivation in Cf2Th but not EREp to 31 (stem-loop 1) was eliminated; in pTD32–69 and
cells permissive for viral infection pTD44–102 structures defined by nt 32 to 68 (stem-loop
2) and 69–100 (stem-loop 3) were disrupted while stem-We and others have previously determined by reporter
loop 1 was retained; in pTD1–111 all three potentialgene assay that BIV Tat can effect strong transactivation
stem-loops were eliminated. Several variations on theof the BIV LTR in EBL, Madin-Darby kidney, and Cf2Th
structure presented in Fig. 6A are predicted using alteredcells (Liu et al., 1992; Pallansch et al., 1992; Carpenter
energy and sequence length parameters. However,et al., 1993; Fong et al., 1995). However, only weak trans-
stem-loop 1 is retained over a broad spectrum of ener-activation can be detected in virally permissive BLAC-
gies and RNA lengths (data not presented). Schematic20 and EREp cells (Fong et al., 1995). To extend our
maps showing the locations of the R region deletionsunderstanding of BIV Tat transactivation and map regions
are presented in Fig. 6B.of the protein and LTR required for activity, we con-
structed two plasmids in which expression of Tat103 and We initially examined the transactivation potential of
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TABLE 1
Nucleotide Substitutions in Complete BIV Tat cDNA Clonesa
Nucleotide
Amino acid
Clone no. Splice typeb Position Change substitution
81 103 687 A Glnr T r Leu
1198 G r A Nonec
108 108 682 C Asp r Glur A
110 103 915 A Noner G
939 C Noner T
123 103 951 C Noner T
960 C Noner A
998 T Noner C
1029 C Noner T
TATC-1d 103 428 A Iler C r Leu
584 G r A Val r Ile
659 A Glur G r Gly
a Changes are relative to nucleotides in the predicted tat mRNA transcripts as presented in Fig. 1.
b Splice variant 103 refers to cDNAs encoding the one exon, 103 amino acid Tat103 species. Splice variant 108 refers to cDNAs encoding the
two exon, 108 amino acid Tat108 species.
c Nucleotide substitutions that occur in untranslated sequences and do not affect the BIV Tat protein amino acid sequence.
d TATC-1 refers to BIV Tat sequence described by Liu et al. (1992).
the Tat expression constructs in Cf2Th cells. Cotransfec- ied significantly in virally infected cells of either type (data
not presented). These results corroborate our previoustion of pBLTRLuc with pTat103 or pTat108 resulted in
approximately 20- and 40-fold increases in luciferase re- findings that TAR is not required for transactivation in
EREp cells (Fong et al., 1995) and demonstrate that theporter gene activity, respectively, relative to that exhibited
by cells transfected with pBLTRLuc alone (Fig. 7A). These Tat basic domain is also dispensable.
Tat plasmids also effected approximately 23- to 93-fold
Tat Transactivation of the BIV LTR can occur in Helatransactivation with deletion constructs in which stem-
and NIH 3T3 cells nonpermissive for viral infectionloop 1 was present (pTD32–69 and pTD44–102), but
less than 3-fold or no activation in constructs where it
To test whether the activity of BIV Tat is restricted only
was deleted (pTD1–31, pTD1–111). With pTat108 the
to virally permissive cell types, we carried out BIV LTR
level of transactivation in the absence of stem-loops 2
transactivation assays with human (Hela) and murine (NIH
and 3 was approximately 2-fold higher than when they
3T3) cells nonpermissive for infection. In Hela cells the
were present. pTat83 similarly effected strong transacti-
pattern of BIV Tat transactivation paralleled that observed
vation of reporter gene plasmids containing stem-loop 1,
in Cf2Th cells (Fig. 7C). Approximately 10- to 20-fold trans-
but pTat64 (basic and carboxyl-terminal domains de-
activation occurred with pTat103, pTat108, and pTat83 us-
leted) failed to transactivate any of the reporter con-
ing BIV LTR luciferase plasmids where TAR stem-loop 1
structs more than 2-fold.
was present. Less than 3-fold or no transactivation occurred
Using EREp cells, all the Tat plasmids effected only 2-
with constructs where stem-loop 1 was deleted or where
to 5-fold transactivation (Fig. 7B). The level of activation
pTat64 was used as the transactivator plasmid. Results
was approximately the same with reporter constructs
similar to these were obtained with NIH 3T3 cells, except
where stem-loop 1 was deleted (pTD1–31, pTD1–111)
that the level of TAR-dependent transactivation (approxi-
as with those where it was present (pBLTRLuc and
mately 21- to 34-fold) was higher (Fig. 7D).
pTD32–69). The lower transactivation in EREp cells rela-
tive to Cf2Th cells was unlikely due to lower expression BIV Tat can cross-transactivate the HIV-1 LTR in a
of Tat from the cytomegalovirus promoter in pTat103 and TAR-dependent manner in Cf2Th but not EREp, Hela,
pTat108, as transfection of both cell types with a pRcCMV or NIH 3T3 cells
derivative in which expression of chloramphenicol acetyl-
transferase was under the control of the cytomegalovirus BIV Tat has been shown to cross-transactivate the HIV-
1 LTR (Liu et al., 1992). To determine whether cross-trans-promoter resulted in similarly high levels of reporter gene
expression (data not presented). In addition, there was activation involves an interaction with the HIV-1 TAR se-
quence, we carried out transient transfection reporter geneno evidence from RIPA or immunoelectron microscopy
analysis that the expression or cell trafficking of Tat var- assays with an HIV-1 LTR luciferase reporter plasmid
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FIG. 2. Homology of tat 108 to other lentiviral tat gene sequences. (A) Dendrogram of lentiviral Tat relationships. The Tat proteins of ovine,
caprine, equine, feline, bovine, nonhuman primate, and human lentiviruses were analyzed by a PileUp program (Feng and Doolittle, 1987) in the
UWGCG sequence analysis package. The program creates a multiple sequence alignment from a group of related sequences using progressive
pairwise alignments and uses these to plot a tree showing a clustering of the relationships. (B) Comparative structural domains of HIV-1, SIV, and
BIV Tat proteins. Cysteine-rich and basic domains are underlined. The ends of the BIV Tat open reading frames in pTat64 and pTat83 are indicated
by arrows (F) under the Tat103 sequence. RGD and KGD motifs present in HIV-1 Tat and BIV Tat108, respectively, are enlarged.
(pHLTRLuc) and a derivative of this construct in which the vated pHLTRLuc-directed reporter gene expression, ef-
fecting 44- to 62-fold increases in activity, respectively, rela-HIV-1 TAR stem-loop was disrupted (pHdTARLuc). We first
tested whether these plasmids would permit transactivation tive to that exhibited by pHLTRLuc alone (Fig. 8A). With
pTat64, a more moderate (approximately 11-fold) level ofby the cognate HIV-1 Tat protein in our experimental system
by carrying out transfection assays with an expression vec- transactivation occurred. All of the BIV Tat plasmids also
transactivated pHdTARLuc, but for constructs containingtor, pHTat72, in which synthesis of HIV-1 Tat was directed
by the Rous sarcoma virus promoter. Strong, TAR-depen- the basic domain (pTat103, pTat108, and pTat83) the level
of activation (approximately 14- to 18-fold) was lower thandent transactivation was observed in Cf2Th and Hela cells
(Figs. 8A and 8C, respectively). No significant transactiva- that observed using pHLTRLuc as a reporter plasmid. In
contrast, none of the BIV Tat plasmids transactivatedtion was detected in EREp or NIH 3T3 cells (Figs. 8B and
8D, respectively). We next examined the ability of the BIV pHLTRLuc- or pHdTARLuc-directed luciferase expression
more than 4-fold in EREp, Hela, and NIH 3T3 cells (Figs.Tat expression vectors to cross-transactivate the HIV-1 LTR.
In Cf2Th cells, pTat103, pTat108, and pTat83 strongly acti- 8B–8D, respectively).
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trast, in EREp, Hela, and NIH 3T3 cells the strength of
transactivation effected by each Tat plasmid was approx-
imately the same at all plasmid concentrations employed
(data not presented). We also examined the effect of
transfecting cells with both Tat plasmids in increasing
concentrations. In Cf2Th cells the level of transactivation
in the presence of both Tat plasmids was intermediate
between that achieved using the plasmids individually,
indicating that Tat103 and Tat108 cannot interact syner-
gistically (Fig. 10). In the other three cell types the level
FIG. 3. Detection of BIV Tat in bacterial and virally infected cells by of transactivation obtained with both plasmids was not
RIPA. (A) RIPA of bacterial and mammalian cells metabolically labeled significantly or consistently different than that obtained
with [35S]methionine and [35S]cysteine. Antigen used in lanes 1, IPTG-
using the plasmids singularly (data not presented).induced pT5m-Tat transformed E. coli; 2, uninduced pT5m-Tat trans-
formed E. coli; 3, 5, and 7, BIV127-infected BLAC-20 cells; 4, 6, and 8,
BIV Tat is required for virus replication in both Cf2Thuninfected BLAC-20 cells. Antisera used in lanes 1 through 4, anti-Tat-
2 serum; 5 and 6, anti-Tat-3 serum; 7 and 8, anti-recombinant Tat serum. and EREp cells
(B) RIPA of BIV-infected cells metabolically labeled with 32Pi . Antisera
To test the requirement of the BIV tat gene for viralused in lanes 1, normal rabbit negative control; 2, rabbit anti-Tat-3; 3,
rabbit anti-Rev peptide sera. The positions of a BIV Tat species of 14 replication, we engineered a BIV127 proviral derivative,
kDa and a potential dimeric protein of 28 kDa are indicated by asterisks
(*). In both (A) and (B), molecular mass markers (kDa) and viral proteins
(vp) are indicated on the left and right of the figures, respectively.
HIV-1 Tat cannot cross-transactivate the BIV LTR in a
TAR-dependent manner
As a comparison, we also tested the ability of HIV-
1 Tat to cross-transactivate the BIV LTR reporter gene
plasmids. Using pHTat72, approximately 2- to 5-fold acti-
vation of all of the BIV LTR constructs was observed in
Cf2Th, EREp and Hela cells (Figs. 9A–9C, respectively).
There was no correlation between the presence or ab-
sence of BIV TAR and the level of activation observed.
HIV-1 Tat did not stimulate luciferase expression with
any of the BIV LTR reporter gene plasmids in NIH 3T3
cells (Fig. 9D).
Tat108 is a moderately stronger transactivator of the
BIV LTR than Tat103 in Cf2Th but not in EREp, Hela,
and NIH 3T3 cells
Although the amino-terminal, conserved core, cys-
teine-rich, and basic Tat regions are sufficient for TAR-
dependent transactivation, the differing structures of
Tat103 and Tat108 at their carboxyl-termini suggested
that these proteins might have variant functional quali-
ties. One possibility in this regard is that they differ in
their relative transactivation strengths. To test this hy-
pothesis we carried out transient transfection reporter
gene assays with pBLTRLuc and increasing amounts of
pTat103 and pTat108. In Cf2Th cells pTat108 effected
FIG. 4. Subcellular localization of Tat protein in BIV-infected cells byapproximately 2.5- to 5-fold greater transactivation than
indirect immunofluorescence. (A) Uninfected and (B) BIV127-infectedpTat103 at all Tat plasmid DNA concentrations greater
Cf2Th cells were stained with rabbit anti-Tat-3 serum, followed by fluo-
than 50 ng per well (Fig. 10). Results similar to these rescein isothiocyanate-labeled goat anti-rabbit IgG, and visualized and
were obtained in four out of five separate assays using photographed using a fluorescence-equipped Leitz Orthoplan micro-
scope.Tat plasmids prepared on two separate dates. By con-
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FIG. 5. Ultrastructural determination of the subcellular location of BIV Tat by immunoelectron microscopy. (A) Uninfected Cf2Th cells; (B and C)
BIV127-infected Cf2Th cells. Inset in (C) is enlargement of boxed area in nucleolus. Location of the cytoplasm, nucleus, and nucleolus are indicated
by (Cy), (N), and (n), respectively. Magnification bar in (A, B, and C), 1 mM; in inset, 0.2 mM. Cells were stained with rabbit anti-Tat-3, followed by
colloidal gold-labeled goat anti-rabbit IgG. Immunolabeled sections on the grid were then stained for transmission electron microscopy and visualized
using a Hitachi H-7000 electron microscope.
pBIV127Dtat, in which a TAG stop codon was introduced mately 2 weeks after proviral DNA transfection (Figs.
11A–11C). With BIV127Dtat replication could not be de-30 amino acids downstream of the tat gene Met initiator.
Plasmid DNA for this mutant or the parental BIV127 strain tected over a 20-day observation period in Cf2Th or EREp
cells (Figs. 11A and 11C, respectively), but was readily(pBIV127) was transfected into Cf2Th, Cf2Th-Tat103 cells
that stably expressed Tat103, or EREp cells, and the level detected in Cf2Th-Tat103 cells less than 2 weeks after
DNA transfection (Fig. 11B). The replication observed inof virus particles released into the culture medium over
time determined by a sensitive p26 antigen capture Cf2Th-Tat103 cells indicates that the defect in BIV127Dtat
could be complemented in trans by Tat103. Similar com-assay. Replication of the parental BIV127 strain occurred
in all three cell types, with peak titers occurring approxi- plementation analysis was not performed with EREp cells
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circumvent this problem we tried cotransfecting EREp
cells with pTat103 and BIV127Dtat in an attempt to com-
plement the tat defect by a transient transfection ap-
proach. This effort proved unsuccessful, possibly be-
cause cells initially transfected with pTat103 were rapidly
overgrown by nontransfected cells in a manner that ob-
scured our ability to detect complementation of virus rep-
lication (data not presented).
DISCUSSION
In this study, Tat-specific cDNAs from BIV-infected
cells were cloned and sequenced and an analysis was
made of the proteins they specify. We show that BIV
encodes two Tat proteins, Tat103 and Tat108, derived by
alternative splicing of mRNAs composed of three exons.
For Tat103, only the second exon is coding, whereas for
Tat108 coding is specified both by the second exon and
a short portion of the third. The resulting proteins are
identical except for their carboxyl-terminal sequences.
The structure of the tat 103 mRNAs is similar to that of
unspliced tat mRNAs encoded by HIV-1, HIV-2, and SIV,
which also contain an in-frame stop codon at the end of
their first coding exons (Myers et al., 1988).
The RIPA data demonstrated that BIV Tat is phosphory-
lated (Fig. 3B) and suggests that BIV Tat transactivation
is mediated by kinase activity. Consistent with this possi-
bility, HIV-2 Tat has also been shown to be phosphory-
lated (Hermann and Rice, 1993), and recent studies indi-
cate that both HIV-1 and HIV-2 Tat associate with a cellu-
lar kinase in a manner that contributes to transactivation
(Hermann and Rice, 1995). RIPA data additionally demon-
strated that BIV Tat expressed in virally infected cells
migrates as a monomeric 14-kDa protein and a poten-
tially dimeric 28-kDa species. Without further analysis it
is not clear whether the 28-kDa species represents a Tat
homodimer or a complex between Tat and a heterolo-
gous protein. HIV-1 Tat expressed in E. coli has been
shown to form metal-linked homodimers (Frankel et al.,
1988). However, attempts to demonstrate a similar phe-
nomenon with mammalian cell expressed HIV-1 Tat have
failed (Ruben et al., 1989), and a link between the trans-
activation potential of HIV-1 Tat and dimerization has yet
FIG. 6. Structure of BIV R region RNA and schematic maps of to be established.
pBLTRLuc and pBLTRLuc derivatives. (A) Potential structure of RNA Our observation that BIV Tat exhibits a uniquely nucle-
transcribed from nt 1 to 100 of the BIV LTR R region as determined by olar accumulation (Figs. 4 and 5) is distinct from what
the RNA fold program of Zuker and Stiegler (1981). (B) Schematic map
has been found for HIV-1 Tat (Hauber et al., 1987; Falknerof BIV U3, R, and U5 regions present in pBLTRLuc and R region deletion
et al., 1988; Miyazaki et al., 1992), and Rev proteins en-constructs (pTD1-31, pTD32-69, pTD44-102, pTD 1–111) derived from
it. The deleted R region sequences are indicated by gaps. Within the coded by BIV, HIV-1, CAEV, and visna virus (Oberste
BIV LTR sequence cloned into pBLTRLuc, the U3, R, and U5 regions et al., 1993; Miyazaki et al., 1992; Saltarelli et al., 1994;
consist of nt 0384 to 01, /1 to /112, and /113 to /144, respectively. Schoberg and Clements, 1994), which exhibit both nu-
clear and nucleolar localizations. The reasons for this
difference may involve residues in the basic domain ofbecause they do not represent a stable cell line and it is
thus difficult to generate derivatives of them expressing a BIV Tat, as the corresponding region in HIV-1 Tat has
been shown to play an important role in protein targetingforeign gene using standard drug selection protocols. To
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FIG. 7. Effect of cell type on TAR-dependent transactivation of the BIV LTR by BIV Tat. Transactivation of pBLTRLuc, pTD1-31, pTD32-69, pTD44-
102, and pTD1-111 reporter gene expression by Tat proteins encoded by pTat103, pTat08, pTat83, and pTat64 was determined by transient
transfection assay in (A) Cf2Th; (B) EREp; (C) Hela; and (D) NIH 3T3 cells. Transfection conditions were as described under Materials and Methods.
Fold transactivation was calculated as the level of luciferase reporter gene expression in the presence of Tat plasmid divided by the level in the
absence of added plasmid. Each value represents the average of three wells. The reporter gene and Tat plasmids used for each condition are
indicated to the left of each figure.
(Dang and Lee, 1989; Endo et al., 1989; Kuppuswamy et Frankel, 1992) and would be expected to localize only in
the nucleus, not the nucleolus, which primarily serves asal., 1989; Ruben et al., 1989; Siomi et al., 1990). The
nucleolar trafficking of both BIV and HIV-1 Tat is unex- a site of rRNA synthesis and ribosome assembly. One
explanation for these results is that transactivation re-pected, given strong evidence that lentiviral Tats primar-
ily act through a transcriptional mechanism (reviewed in quires only a transient presence of Tat in the nucleus. If
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FIG. 8. Effect of cell type on TAR-dependent transactivation of the HIV-1 LTR by BIV Tat and HIV-1 Tat. Transactivation of pHLTRLuc and pHdTARLuc
reporter gene expression by Tat proteins encoded by pTat103, pTat08, pTat83, pTat64, and pHTat72 was determined by transient transfection assay
in (A) Cf2Th; (B) EREp; (C) Hela; and (D) NIH 3T3 cells. Transfection conditions were as described under Materials and Methods. Fold transactivation
was calculated as described in the legend to Fig. 7. Each value represents the average of three wells. The reporter gene and Tat plasmids used
for each condition are indicated to the left of each figure.
true an equilibrium may exist between transcriptionally HIV-1 Tat have yielded conflicting results (Pearson et al.,
1990; Mann and Frankel, 1991).active Tat in the nucleus and nonutilized Tat in the nucle-
olus which strongly favors nucleolar localization. Alterna- Our reporter gene assays and deletion mapping analy-
sis demonstrate that both Tat103 and Tat108 can stronglytively, Tat present in the nucleolus may have the potential
to interact functionally with the transcription apparatus. transactivate the BIV LTR in Cf2Th, Hela, and NIH 3T3
cells and that this phenomenon requires stem-loop 1 andIn support of this, studies by Carter et al. (1991) have
shown that sites of poly(A) RNA transcription concentrate the basic domain common to both proteins. In addition
to the deletion mapping analysis, several other observa-in discrete nuclear domains that surround the nucleolus.
Thus far, studies designed to establish a relationship tions indicate that TAR consists only of stem-loop 1 and
not stem-loops 2 and 3. First, based on an RNA foldbetween nucleolar localization and transactivation for
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FIG. 9. Effect of cell type on cross-transactivation of the BIV LTR by HIV-1 Tat. Cross-transactivation of pBLTRLuc, pTD1-31, pTD32-69, pTD44-
102, and pTD1–111 reporter gene expression by pHTat72 was determined by transient transfection assay in (A) Cf2Th; (B) EREp; (C) Hela; and (D)
NIH 3T3 cells. Transfection conditions were as described under Materials and Methods. Fold transactivation was calculated as described in the
legend to Fig. 7. Each value represents the average of three wells. Black bars, no added pHTat72 plasmid. Stippled bars, pHTat72 plasmid present.
The reporter gene plasmids used for each condition are indicated to the left of each figure.
algorithm program (Zuker and Stiegler, 1981), stem-loop basic region can specifically bind stem-loop 1 nt 10 to
25 (Chen and Frankel, 1994). The identification of BIV1 is stable for viral RNAs of varying length, whereas the
structures of stem-loops 2 and 3 vary considerably (data TAR as nt /1 to /31 contrasts with studies showing that
transactivation of the HIV-2 LTR is facilitated by bothnot presented). Second, removal of sequences down-
stream of stem-loop 1 did not reduce the level of TAR- distal and proximal stem-loops in its TAR sequence (Ber-
khout et al., 1990).dependent transactivation. Finally, biochemical studies
have determined that peptides derived from the BIV Tat The results of our Tat and LTR R region deletion analy-
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tion in NIH 3T3 cells. The latter may indicate that NIH
3T3 cells lack cellular proteins which are required for
HIV-1 Tat–TAR binding but are dispensable for the BIV
interaction. In support of this, the BIV Tat–TAR interaction
has been shown to be stronger than that of HIV-1 and,
unlike the latter, to not require cellular proteins for stabili-
zation (Chen and Frankel, 1994). Another possibility is
that NIH 3T3 cells contain a complement of transcription
factors that are able to positively interact with the BIV
but not the HIV-1 LTR U3 region. A number of studies
have shown that lentivirus transactivation and the cell
types that permit it are influenced by the nature of U3
region transcription factor binding elements (Hess et al.,
1989; Berkhout and Jeang, 1992; Maury et al., 1994).
Cross-transactivation studies indicate that Cf2Th cells
contain factors that permit a TAR-dependent interaction
of BIV Tat with the HIV-1 LTR, but not the reciprocal
phenomenon. Cf2Th cells were also found to be permis-
sive for TAR-dependent transactivation of the HIV-1 LTR
FIG. 10. Transactivation potential of Tat103 and Tat108. Comparison by HIV-1 Tat. The latter has been described earlier
of pTat103 and pTat108 transactivation potential using pBLTRLuc as a (Maury et al., 1994) and adds to evidence that HIV-1
reporter gene plasmid in Cf2Th cells. When used singularly, the level transactivation is not limited to primate cells (Murphy et
of the added Tat plasmids was varied between 0 and 500 ng per well.
al., 1993). An analysis of factors present in Cf2Th cellsWhen pTat103 and pTat108 were added together, the level of each
that permit transactivation of the HIV-1 LTR by its cognateplasmid was varied between 0 and 250 ng per well, resulting in a total
Tat plasmid addition of 0 to 500 ng per well. Transfection conditions and BIV Tat may help reveal the mechanisms responsible
were as described under Materials and Methods. Fold transactivation for specific RNA–protein interactions and gene activa-
was calculated as described in the legend to Fig. 7. Each value repre- tion that result from it.
sents the average of three wells. Filled squares (j), pTat108; open
The observation that Tat 108 is a more potent transacti-squares (h), pTat103; crosses ( ), mixture of pTat108 and pTat103.
vator than Tat103 in Cf2Th cells indicates that the car-
boxyl-terminal regions of both proteins, while dispens-
able for transactivation, can influence activation strength.ses are in general agreement with data from primate
lentivirus Tat studies showing that an interaction be- The presence of the carboxyl-terminal regions specified
by the second coding exons of HIV-1 and SIV tat havetween the basic domain and TAR mediates transactiva-
tion (Frankel, 1992). However, BIV Tat differs from the also been shown to stimulate transactivation (Viglianti
and Mullins, 1988). With HIV-1 this phenomenon may inprimate lentivirus Tats in being able to effect transactiva-
FIG. 11. Requirement of the BIV tat gene for viral replication. The replication kinetics of BIV127 and BIV127Dtat were determined by CA antigen
capture assay in (A) Cf2Th; (B) Cf2Th-Tat103; and (C) EREp cells. Experimental conditions were as described under Materials and Methods. Filled
squares (j), replication of BIV127; open diamonds (L), replication of BIV127Dtat. Each value represents the average of replicate wells.
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part be due to the presence of an integrin receptor bind- These studies show that while BIV and HIV-1 Tat are
similar in structure and function, they vary significantlying motif (RGD) in the third tat exon. This motif mediates
a Tat paracrine effect wherein biologically active protein in the molecular processes by which they effect transacti-
vation. Determination of the precise amino acid differ-is released from virally infected or Tat-expressing cells
and readily endocytosed and targeted to the nucleus of ences responsible for this phenomenon will shed light
on the mechanisms underlying lentivirus gene regulation.nearby cells, where it can mediate a series of effects,
including stimulation of HIV-1 LTR-directed gene expres-
sion (Barillari et al., 1993; Ensoli et al., 1993; Zauli et al.,
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